Allison L Naleway1, Samantha Kurosky2, Michelle L Henninger2, Rachel Gold2, James D Nordin3, Elyse O Kharbanda3, Stephanie Irving4, T Craig Cheetham5, Cynthia Nakasato6, Jason M Glanz7, Simon J Hambidge8, Robert L Davis9, Nicola P Klein10, Natalie L McCarthy11, Eric Weintraub11. 1. Center for Health Research (Naleway, Kurosky, Henninger, Gold, Irving), Kaiser Permanente Northwest, Portland, Oregon. Electronic address: allison.naleway@kpchr.org. 2. Center for Health Research (Naleway, Kurosky, Henninger, Gold, Irving), Kaiser Permanente Northwest, Portland, Oregon. 3. the HealthPartners Institute for Education and Research (Nordin, Kharbanda), Minneapolis, Minnesota. 4. Center for Health Research (Naleway, Kurosky, Henninger, Gold, Irving), Kaiser Permanente Northwest, Portland, Oregon; the Marshfield Clinic Research Foundation (Irving), Marshfield, Wisconsin. 5. the Department of Research and Evaluation and Pharmacy Analytical Services (Cheetham), Kaiser Permanente Southern California, Downey. 6. the Center for Health Research (Nakasato), Kaiser Permanente Hawaii, Honolulu, Hawaii. 7. the Institute for Health Research (Glanz, Hambidge), Kaiser Permanente Colorado. 8. the Institute for Health Research (Glanz, Hambidge), Kaiser Permanente Colorado; the Community Health Pediatrics (Hambidge), Denver Health, Denver, Colorado. 9. the Center for Health Research (Davis), Kaiser Permanente Georgia. 10. the Kaiser Permanente Vaccine Study Center (Klein), Oakland, California. 11. the Immunization Safety Office (McCarthy, Weintraub), CDC, Atlanta, Georgia.
Abstract
BACKGROUND: A number of studies have described influenza vaccination coverage during pregnancy but few publications have described rates of other vaccinations. PURPOSE: To describe vaccination rates during pregnancy in the Vaccine Safety Datalink (VSD), with particular focus on vaccinations contraindicated during pregnancy. METHODS: Pregnancies ending in 2002 through 2009 and vaccinations administered during these pregnancies were identified in the VSD. Vaccination rates per 1000 pregnancies during the study period were calculated by vaccine type, recommendation category, pregnancy year, maternal age, and trimester. Analyses were conducted in 2012-2013. RESULTS: In the VSD, 669,695 pregnancies and 141,389 vaccinations were identified. Trivalent inactivated influenza (TIV) was the most commonly administered vaccination (174.1 doses per 1000 pregnancies) and was most often administered during the 2nd and 3rd trimesters. The most common vaccines in the "consider if indicated" category were tetanus-diphtheria (6.1 per 1000) and hepatitis B (3.7 per 1000). Contraindicated vaccination was infrequent, and the majority of these were measles-mumps-rubella (MMR) (1.2 per 1000); varicella (1.0 per 1000); and live-attenuated influenza vaccine (LAIV) (0.3 per 1000). Both "consider if indicated" and contraindicated vaccines were more frequently administered during early pregnancy. CONCLUSIONS: TIV was the most commonly administered vaccine. With the exception of TIV, other vaccines were most frequently administered during early pregnancy and among younger women, suggesting that vaccination may occur when the woman and/or provider are unaware of the pregnancy. Contraindicated vaccines were infrequently administered during pregnancy; however, given that some women received contraindicated vaccines later in pregnancy, clearer recommendations and improved provider education may be needed.
RCT Entities:
BACKGROUND: A number of studies have described influenza vaccination coverage during pregnancy but few publications have described rates of other vaccinations. PURPOSE: To describe vaccination rates during pregnancy in the Vaccine Safety Datalink (VSD), with particular focus on vaccinations contraindicated during pregnancy. METHODS: Pregnancies ending in 2002 through 2009 and vaccinations administered during these pregnancies were identified in the VSD. Vaccination rates per 1000 pregnancies during the study period were calculated by vaccine type, recommendation category, pregnancy year, maternal age, and trimester. Analyses were conducted in 2012-2013. RESULTS: In the VSD, 669,695 pregnancies and 141,389 vaccinations were identified. Trivalent inactivated influenza (TIV) was the most commonly administered vaccination (174.1 doses per 1000 pregnancies) and was most often administered during the 2nd and 3rd trimesters. The most common vaccines in the "consider if indicated" category were tetanus-diphtheria (6.1 per 1000) and hepatitis B (3.7 per 1000). Contraindicated vaccination was infrequent, and the majority of these were measles-mumps-rubella (MMR) (1.2 per 1000); varicella (1.0 per 1000); and live-attenuated influenza vaccine (LAIV) (0.3 per 1000). Both "consider if indicated" and contraindicated vaccines were more frequently administered during early pregnancy. CONCLUSIONS: TIV was the most commonly administered vaccine. With the exception of TIV, other vaccines were most frequently administered during early pregnancy and among younger women, suggesting that vaccination may occur when the woman and/or provider are unaware of the pregnancy. Contraindicated vaccines were infrequently administered during pregnancy; however, given that some women received contraindicated vaccines later in pregnancy, clearer recommendations and improved provider education may be needed.
Authors: Mohammad Ali; Allyson Nelson; Francisco J Luquero; Andrew S Azman; Amanda K Debes; Maurice Mwesawina M'bang'ombe; Linly Seyama; Evans Kachale; Kingsley Zuze; Desire Malichi; Fatima Zulu; Kelias Phiri Msyamboza; Storn Kabuluzi; David A Sack Journal: Lancet Infect Dis Date: 2017-02-02 Impact factor: 25.071
Authors: Elyse O Kharbanda; Gabriela Vazquez-Benitez; Malini B DeSilva; Alicen B Spaulding; Matthew F Daley; Allison L Naleway; Stephanie A Irving; Nicola P Klein; Hung Fu Tseng; Lisa A Jackson; Simon J Hambidge; Oluwatosin Olaiya; Catherine A Panozzo; Tanya R Myers; Paul A Romitti Journal: Pharmacoepidemiol Drug Saf Date: 2020-12-03 Impact factor: 2.732
Authors: Annette K Regan; Donna B Mak; Hannah C Moore; Lauren Tracey; Richard Saker; Catherine Jones; Paul V Effler Journal: BMC Public Health Date: 2015-11-23 Impact factor: 3.295
Authors: Allison L Naleway; Bradley Crane; Stephanie A Irving; Don Bachman; Kimberly K Vesco; Matthew F Daley; Darios Getahun; Sungching C Glenn; Simon J Hambidge; Lisa A Jackson; Nicola P Klein; Natalie L McCarthy; David L McClure; Lakshmi Panagiotakopoulos; Catherine A Panozzo; Gabriela Vazquez-Benitez; Eric S Weintraub; Ousseny Zerbo; Elyse O Kharbanda Journal: Ther Adv Drug Saf Date: 2021-06-14